Unlocking the potential of gene therapy for patients with rare and orphan diseases

About Medgenics

At Medgenics, we share one singular focus - to transform the lives of our patients through the development of innovative and best-in-class therapies. We are dedicated to developing the company’s unique technology platform for the express purpose of treating patients with rare genetic and orphan diseases.


The BioPump has demonstrated several advantages over current gene or protein therapy, including efficacy, safety and capital efficiency.

Latest News

09-10-14 Medgenics Announces the Appointment of Scott Applebaum as Chief Legal Officer 07-16-14 Medgenics Reports Second Quarter Financial Results 06-18-14 Medgenics Announces Global Head, Research and Development, Garry Neil, M.D. Receives FDA Commissioner's Special Citation Award